ADVANZ PHARMA Brings Key Changes in Senior Management to Further Accelerate Next Phase of Growth
Dr. Steffen Wagner appointed new general manager and Andreas Stickler as the new CFO
LONDON, November 18, 2021 / PRNewswire / – ADVANZ PHARMA Corp. Limited (“ADVANZ PHARMA” or “the Company”), a specialty pharmaceutical company that strategically focuses on complex drugs in Europe, today announced several changes in leadership roles as it enters the next phase of its growth path.
Dr. Steffen Wagner is to become the new Managing Director of ADVANZ PHARMA, from the start of 2022. He succeeds Graeme Duncan, who will step down and become special advisor to the board of directors. Andreas Stickler will join Merck Healthcare as new CFO, succeeding Adel Ahmad.
Dr. Steffen Wagner is currently a member of the management team of STADA Arzneimittel AG and was responsible for the European Markets division of the company. Steffen is a Doctor of Medicine by training, previously held management positions at Biogen and the Novartis Group, and worked as a consultant at McKinsey & Company and Bain & Company. He brings a wealth of international pharmaceutical experience which will be invaluable in supporting ADVANZ PHARMA’s continued journey. His predecessor, Graeme Duncan, has been part of ADVANZ PHARMA since 2014 and has played an important role in building the Company to this day. He will continue to work with the Council as a special advisor.
Andreas Stickler will join as the new CFO of the Company in January 2022. Most recently, he was CFO of Merck Healthcare, part of Merck KGaA, where he also served as Global Director of Mergers & Acquisitions and Business Development, leading major strategic acquisitions. He brings to the team extensive expertise in global finance, healthcare, and mergers and acquisitions. His predecessor, Adel Ahmad, has been with the company since 2013 and has contributed to the completion of major transformation projects and the construction of a sustainable business from which to grow.
These two key additions to the ADVANZ PHARMA management team are accompanied by several other management changes. At November 1, 2021, Susanna El-Armale joins as Head of Business Development, following his previous role as Head of Business Development at Theramex and succeeding the former Head of Business Development Guy clark. Susanna brings extensive experience spanning both M&A and business management activities and will be a central driver of the company’s active business development program. In January 2022, Chris Britten will join that of Susanna El-Armale as Senior Vice President M&A, following his role as Head, M&A for Neuraxpharm. At October 11, Anke Niedernberg has joined us as Senior Vice President and Head of Transformation Office. She brings a wide range of skills to the management team, having spent time in private equity advising and leading major change and growth projects for Sandoz over the past ten years.
These leadership changes build on ADVANZ PHARMA’s success in 2021 and will help fuel the next phase of the company’s growth. In 2021, the Company maintained a strong financial performance, successfully acquired additional strategic assets, began the European launch of a generic version of Lanreotide and strengthened its organic pipeline with new license agreements. ADVANZ PHARMA continues to make progress towards realizing its corporate vision of becoming the “partner of choice” for complex specialties and hospital medicines in Europe.
About ADVANZ PHARMA
ADVANZ PHARMA is headquartered in London and has commercial subsidiaries in Europe, North America and Australia, and the supply chain, regulatory and administrative operations in India. In addition, ADVANZ PHARMA has an established global network of business partners in the rest of the world. With an agile and experienced team including direct sales, marketing and medical capabilities in many Europe key markets, ADVANZ PHARMA supplies, innovates and improves the essential medicines on which patients depend, ensuring continued access to patients and improving healthcare outcomes. ADVANZ PHARMA has extensive expertise in several therapeutic areas with strengths in the therapeutic areas of intensive care, anti-infective, endocrinology, cardiovascular system and central nervous system, as well as direct access to sales in Europe, which makes it an attractive partner for the marketing of complex drugs, particularly in the hospital circuit. To learn more, visit our website: https://www.advanzpharma.com.
View original content to download multimedia:https://www.prnewswire.com/news-releases/advanz-pharma-makes-key-changes-to-senior-leadership-to-further-accelerate-next-phase-of-growth-301427684.html
SOURCE ADVANZ PHARMA Corp.